Studies were carried out on the penetration of
cefuzonam (L-105, CZON), a new synthetic
cephalosporin antibiotic, into cerebrospinal fluid, and on the clinical efficacy against
bacterial infections. The results are summarized as follows: Concentrations of CZON in cerebrospinal fluid at 1 hour after
intravenous administration of 100 mg/kg in cases of
furunculosis of the external canal,
encephalitis and
mumps meningitis were 0.56 micrograms/ml, 1.44 micrograms/ml and 0.33 micrograms/ml, respectively. Concentrations of CZON in cerebrospinal fluid at 1 hour after
intravenous administration of 100 mg/kg in 3 cases of purulent
meningitis were 2.80-6.40 micrograms/ml at the acute stage and 0.56-1.45 micrograms/ml even at the recovering stage. Sensitivities of clinically isolated strains to CZON were determined and expressed as MIC. MICs of CZON on Haemophilus influenzae, Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae were similar to MIC's of
cefmenoxime (CMX), and lower than those of
cefoperazone (CPZ),
cefmetazole (CMZ), cefatiam (CTM) and
Cefazolin (CEZ). The MIC of CZON on Staphylococcus aureus was similar to those of CEZ, CMZ and CTM, and lower than those of CMX and CPZ. Clinical responses of CZON were good in 2 cases of purulent
meningitis, good in 2 cases of
pyothorax, excellent in 1 case of
septicemia, excellent in 3 cases of
urinary tract infections, excellent in 7 cases and good in 3 cases out of 10 cases of
pneumonia. Clinical responses of other diseases were excellent in 4 cases of
bronchitis, good in 1 case of
furunculosis of the external canal, excellent in 1 case of
tonsillitis. No side effects nor abnormal laboratory findings were observed except 2 cases of mild
diarrhea out of 24 cases.